Helical tomotherapy of lymph node-negative early-stage breast cancer after breast-conserving surgery: long-term results

Background/Aim: Adjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surger...

Full description

Saved in:
Bibliographic Details
Main Authors: Zwicker, Felix (Author) , Klepper, Rudolf (Author) , Hauswald, Henrik (Author) , Hoefel, Sebastian (Author) , Raether, Luis (Author) , Huber, Peter E. (Author) , Debus, Jürgen (Author) , Schempp, Michael (Author)
Format: Article (Journal)
Language:English
Published: April 25, 2023
In: Anticancer research
Year: 2023, Volume: 43, Issue: 5, Pages: 2041-2053
ISSN:1791-7530
DOI:10.21873/anticanres.16365
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.21873/anticanres.16365
Verlag, lizenzpflichtig, Volltext: https://ar.iiarjournals.org/content/43/5/2041
Get full text
Author Notes:Felix Zwicker, Rudolf Klepper, Henrik Hauswald, Sebastian Hoefel, Luis Raether, Peter E. Huber, Juergen Debus, Michael Schempp
Description
Summary:Background/Aim: Adjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surgery. Patients and Methods: In this single-centre analysis, 219 female patients with early-stage breast cancer (T1/2) and no lymph node metastasis (N0) following breast-conserving surgery and sentinel-node biopsy were treated with adjuvant fractionated whole breast radiation therapy using helical tomotherapy. When boost irradiation was indicated, it was administered sequentially or using the simultaneous-integrated boost technique. Local control (LC), metastasis and survival rates, acute toxicity, late toxicity, and secondary malignancy rates were analysed retrospectively. Results: The mean follow-up time was 71 months. The 5- and 8-year overall survival (OS) rates were 97.7% and 92.1%, respectively. The 5- and 8-year LC rates were 99.5% and 98.2%, while the 5- and 8-year metastasis-free survival (MFS) rates of 97.4% and 94.3%, respectively. Patients with G3 grading or negative hormone receptor status did not show significantly different results. Acute erythema occurred in 79% (grade 0-2) and 21% (grade 3) of the patients. Lymphedema of the ipsilateral arm and pneumonitis occurred in 6.4% and 1.8% of the treated patients. None of the patients developed >grade 3 toxicities during follow-up, while 1.8% developed a secondary malignancy during follow-up. Conclusion: Helical tomotherapy showed excellent long-term results and low toxicity rates. The incidence rates of secondary malignancy were relatively low and correlated with pre-existing data on radiotherapy, suggesting wider implementation of helical tomotherapy in adjuvant radiotherapy for breast cancer patients.
Item Description:Gesehen am 05.07.2023
Physical Description:Online Resource
ISSN:1791-7530
DOI:10.21873/anticanres.16365